B. Riley Turns Bullish on Capricor Before November Deramiocel Decision
B. Riley upgrades Capricor to Buy from Neutral and lifts its target to $21 from $5 ahead of the Nov. 22, 2026 deramiocel FDA date.
B. Riley upgrades Capricor to Buy from Neutral and lifts its target to $21 from $5 ahead of the Nov. 22, 2026 deramiocel FDA date.
Mizuho, Needham and Guggenheim cite 32–34% script growth and robust 65+ uptake as Auvelity’s Alzheimer’s agitation launch gets off to a strong start.
Lead drug claseprubart (also known as DNTH103) plus $1.2B cash into 2030.
Semaglutide still drives most of Novo Nordisk’s sales. Morgan Stanley and other banks warn the mid-2030s patent cliff and Eli Lilly competition look underpriced.
BBOT dropped ~38% in two days. Stifel, Leerink, Canaccord, and JPMorgan lowered targets but did not downgrade ratings. JPMorgan sees a disconnect vs pipeline value.
Analysts see a likely PFS win in HARMONi-3 later in 2026.